April 2026
M	T	W	T	F	S	S
	1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

Andrew Shaw: Long COVID First Diagnostic Classification with 69% accuracy

Andrew Shaw/LinkedIn

Apr 29, 2026, 15:43

Andrew Shaw: Long COVID First Diagnostic Classification with 69% accuracy

Andrew Shaw, CEO and Founder of Attomarker Ltd, shared a post on LinkedIn:

“Long COVID – first diagnostic classification – 69% accuracy.

We have been looking at over 500 long COVID patients using the COVID Antibody Spectrum Test from Attomarker and there are some clear different types of patients – endotypes.

In our recent paper, we show there are three types of patient or endotypes:

one type has gaps in their antibody spectrum that could lead to persistent virus;
one type has a very large immune response some associated with a vaccine
and a final type that looks normal.

For the first time, we have put a test through a diagnosis accuracy study and found that overall it is 69% accurate a predicting long COVID.

This is a great start given the full set of symptoms that may or may not describe long COVID.

The two endotypes, hypo-immune (65% of patients) and hyper-immune (10% of patients) point to causes of the long COVID and potential treatments.

The Long COVID is fundamentally heterogenous, not all patients are the same – does this explain why all interventional trials are struggling to get good results?

Below is a list of drugs and interventions mentioned on our WhatsApp group but can the right intervention for all endotypes?

Indeed, it may be dangerous to give monoclonal antibodies to patients who have a hyper-immune endotype. Some clinicians are now using the antibody spectrum to target interventions but is it getting better results.

But the journey to recovery is complex especially for the patients who have had symptoms for 5 years now. Maybe it is important to catch patients early with the first signs long COVID symptoms – about 3%-5% of recent infections are still leaving patients with Long COVID.

The test is available worldwide with a number of regulatory hurdles to full adoptions but with a cohort of now more than 500 patients tested, the results are beginning to look promising scientifically.

We need the clinicians to turn the science into medicine.”

Andrew Shaw